Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 275

1.

Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype.

Haage P, Kronstrand R, Josefsson M, Calistri S, van Schaik RHN, Green H, Kugelberg FC.

Pharmacol Res Perspect. 2018 Jul 5;6(4):e00419. doi: 10.1002/prp2.419. eCollection 2018 Jul.

2.

CYP3A5 and ABCB1 polymorphisms in living donors do not impact clinical outcome after kidney transplantation.

Yang L, de Winter BC, van Schaik RH, Xie RX, Li Y, Andrews LM, Shuker N, Bahmany S, Koch B, van Gelder T, Hesselink DA.

Pharmacogenomics. 2018 Jul 1;19(11):895-903. doi: 10.2217/pgs-2018-0066. Epub 2018 Jul 11.

PMID:
29991328
3.

Liquid Biopsies to Monitor Solid Organ Transplant Function: A Review of New Biomarkers.

Verhoeven JGHP, Boer K, Van Schaik RHN, Manintveld OC, Huibers MMH, Baan CC, Hesselink DA.

Ther Drug Monit. 2018 Jun 26. doi: 10.1097/FTD.0000000000000549. [Epub ahead of print]

PMID:
29957668
4.

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z.

Nat Commun. 2018 Jun 11;9(1):2256. doi: 10.1038/s41467-018-04109-8.

5.

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Dominguez MG, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA; Profile Study, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA.

Nat Genet. 2018 Jun 11. doi: 10.1038/s41588-018-0142-8. [Epub ahead of print]

PMID:
29892016
6.

A gene variant near ATM affects the response to metformin and metformin plasma levels: a post hoc analysis of an RCT.

Out M, Becker ML, van Schaik RH, Lehert P, Stehouwer CD, Kooy A.

Pharmacogenomics. 2018 Jun 1;19(8):715-726. doi: 10.2217/pgs-2018-0010. Epub 2018 May 23.

PMID:
29790415
7.

Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial.

van Rongen A, van der Aa MP, Matic M, van Schaik RHN, Deneer VHM, van der Vorst MM, Knibbe CAJ.

Paediatr Drugs. 2018 Aug;20(4):365-374. doi: 10.1007/s40272-018-0293-1.

PMID:
29748932
8.

Toward harmonization of clinical molecular diagnostic reports: findings of an international survey.

Payne DA, Baluchova K, Russomando G, Ahmad-Nejad P, Mamotte C, Rousseau F, van Schaik RHN, Marriott K, Maekawa M, Chan KCA; IFCC Committee on Molecular Diagnostics.

Clin Chem Lab Med. 2018 May 5. pii: /j/cclm.ahead-of-print/cclm-2017-1080/cclm-2017-1080.xml. doi: 10.1515/cclm-2017-1080. [Epub ahead of print]

PMID:
29729139
9.

Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients.

Bins S, Basak EA, El Bouazzaoui S, Koolen SLW, Oomen-de Hoop E, van der Leest CH, van der Veldt AAM, Sleijfer S, Debets R, van Schaik RHN, Aerts JGJV, Mathijssen RHJ.

Br J Cancer. 2018 May;118(10):1296-1301. doi: 10.1038/s41416-018-0074-1. Epub 2018 Apr 26.

PMID:
29695768
10.

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.

de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S.

Clin Pharmacokinet. 2018 Mar 8. doi: 10.1007/s40262-018-0644-7. [Epub ahead of print] Review.

PMID:
29520731
11.

Detection of a rare CYP3A4 variant in a transplant patient characterized by a tacrolimus poor metabolizer phenotype.

Lloberas N, Hesselink DA, van Schaik RH, Grinyò JM, Colom H, Gelder TV, Elens L.

Pharmacogenomics. 2018 Mar;19(4):305-310. doi: 10.2217/pgs-2017-0301. Epub 2018 Feb 22.

PMID:
29469606
12.

Pharmacogenetic Information in Clinical Guidelines: The European Perspective.

Swen JJ, Nijenhuis M, van Rhenen M, de Boer-Veger NJ, Buunk AM, Houwink EJF, Mulder H, Rongen GA, van Schaik RHN, van der Weide J, Wilffert B, Deneer VHM, Guchelaar HJ; Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP).

Clin Pharmacol Ther. 2018 May;103(5):795-801. doi: 10.1002/cpt.1049. Epub 2018 Mar 30. Review.

PMID:
29460273
13.

Accurate determination of the CYP2D6 (*1/*4)xN genotype by quantitative PCR.

Pondman KM, van Schaik RHN, van der Weide J.

Drug Metab Pers Ther. 2018 Mar 28;33(1):33-39. doi: 10.1515/dmpt-2017-0007.

PMID:
29420304
14.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.

Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE.

Clin Pharmacol Ther. 2018 May;103(5):770-777. doi: 10.1002/cpt.1007. Epub 2018 Jan 31.

PMID:
29385237
15.

Creation of the Swiss group of Pharmacogenomics and personalised Therapy (SPT).

Amstutz U, Mlakar V, Curtis PH, Samer C, Baumann P, Bühlmann RP, Meier-Abt P, Meyer UA, van Schaik RHN, Ansari M; Swiss group of Pharmacogenomics and Personalised Therapy.

Drug Metab Pers Ther. 2017 Dec 20;32(4):173-174. doi: 10.1515/dmpt-2017-0033. No abstract available.

PMID:
29267167
16.

Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.

Helland T, Henne N, Bifulco E, Naume B, Borgen E, Kristensen VN, Kvaløy JT, Lash TL, Alnæs GIG, van Schaik RH, Janssen EAM, Hustad S, Lien EA, Mellgren G, Søiland H.

Breast Cancer Res. 2017 Nov 28;19(1):125. doi: 10.1186/s13058-017-0916-4.

17.

Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment.

Del Re M, Bordi P, Petrini I, Rofi E, Mazzoni F, Belluomini L, Vasile E, Restante G, Di Costanzo F, Falcone A, Frassoldati A, van Schaik RHN, Steendam CMJ, Chella A, Tiseo M, Morganti R, Danesi R.

Oncotarget. 2017 Sep 15;8(49):86056-86065. doi: 10.18632/oncotarget.20947. eCollection 2017 Oct 17.

18.

Thiopurine metabolite levels in patients with atopic dermatitis and/or chronic hand/foot eczema treated with azathioprine.

Garritsen FM, van der Schaft J, Bruijnzeel-Koomen CAF, van Schaik RH, de Graaf M, van den Broek MPH, de Bruin-Weller MS.

J Dermatolog Treat. 2018 Jun;29(4):375-382. doi: 10.1080/09546634.2017.1373738. Epub 2017 Sep 26.

PMID:
28914560
19.

Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680-7.

Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik RH, Danesi R.

Eur Urol. 2018 Jan;73(1):e11-e12. doi: 10.1016/j.eururo.2017.07.034. Epub 2017 Aug 9. No abstract available.

PMID:
28801127
20.

Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement.

Matic M, Jongen JL, Elens L, de Wildt SN, Tibboel D, Sillevis Smitt PA, van Schaik RH.

Pharmacogenomics. 2017 Aug;18(12):1133-1142. doi: 10.2217/pgs-2017-0060. Epub 2017 Jul 26.

PMID:
28745577
21.

Reply.

Matic M, van den Bosch GE, de Wildt SN, Tibboel D, van Schaik RHN.

Pain. 2017 Aug;158(8):1623. doi: 10.1097/j.pain.0000000000000945. No abstract available.

PMID:
28715358
22.

A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation.

Andrews LM, Hesselink DA, van Gelder T, Koch BCP, Cornelissen EAM, Brüggemann RJM, van Schaik RHN, de Wildt SN, Cransberg K, de Winter BCM.

Clin Pharmacokinet. 2018 Apr;57(4):475-489. doi: 10.1007/s40262-017-0567-8.

23.

Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation.

Woillard JB, Mourad M, Neely M, Capron A, van Schaik RH, van Gelder T, Lloberas N, Hesselink DA, Marquet P, Haufroid V, Elens L.

Front Pharmacol. 2017 Jun 8;8:358. doi: 10.3389/fphar.2017.00358. eCollection 2017.

24.

Analgesia and Opioids: A Pharmacogenetics Shortlist for Implementation in Clinical Practice.

Matic M, de Wildt SN, Tibboel D, van Schaik RHN.

Clin Chem. 2017 Jul;63(7):1204-1213. doi: 10.1373/clinchem.2016.264986. Review.

25.

Inter-Subject Variability in OCT1 Activity in 27 Batches of Cryopreserved Human Hepatocytes and Association with OCT1 mRNA Expression and Genotype.

Fattah S, Shinde AB, Matic M, Baes M, van Schaik RHN, Allegaert K, Parmentier C, Richert L, Augustijns P, Annaert P.

Pharm Res. 2017 Jun;34(6):1309-1319. doi: 10.1007/s11095-017-2148-9. Epub 2017 Mar 31.

PMID:
28364304
26.

Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose.

Andrews LM, de Winter BC, Tang JT, Shuker N, Bouamar R, van Schaik RH, Koch BC, van Gelder T, Hesselink DA.

Transplant Direct. 2017 Jan 19;3(2):e129. doi: 10.1097/TXD.0000000000000644. eCollection 2017 Feb.

27.

Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach.

Lammers LA, Achterbergh R, van Schaik RHN, Romijn JA, Mathôt RAA.

Clin Pharmacokinet. 2017 Oct;56(10):1231-1244. doi: 10.1007/s40262-017-0515-7.

28.

Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.

Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši Ľ, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Sertić J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, Patrinos GP.

PLoS One. 2017 Feb 16;12(2):e0172595. doi: 10.1371/journal.pone.0172595. eCollection 2017.

29.

Performance Ratio Based Resource Allocation Decision-Making in Genomic Medicine.

Fragoulakis V, Mitropoulou C, Katelidou D, van Schaik RH, Maniadakis N, Patrinos GP.

OMICS. 2017 Feb;21(2):67-73. doi: 10.1089/omi.2016.0161. Epub 2017 Jan 24.

PMID:
28118098
30.

A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach.

Andreu F, Colom H, Elens L, van Gelder T, van Schaik RHN, Hesselink DA, Bestard O, Torras J, Cruzado JM, Grinyó JM, Lloberas N.

Clin Pharmacokinet. 2017 Aug;56(8):963-975. doi: 10.1007/s40262-016-0491-3.

PMID:
28050888
31.

Cohort profile of BIOMArCS: the BIOMarker study to identify the Acute risk of a Coronary Syndrome-a prospective multicentre biomarker study conducted in the Netherlands.

Oemrawsingh RM, Akkerhuis KM, Umans VA, Kietselaer B, Schotborgh C, Ronner E, Lenderink T, Liem A, Haitsma D, van der Harst P, Asselbergs FW, Maas A, Oude Ophuis AJ, Ilmer B, Dijkgraaf R, de Winter RJ, The SH, Wardeh AJ, Hermans W, Cramer E, van Schaik RH, Hoefer IE, Doevendans PA, Simoons ML, Boersma E.

BMJ Open. 2016 Dec 23;6(12):e012929. doi: 10.1136/bmjopen-2016-012929.

32.

Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide, Troponin-T, and Growth-Differentiation Factor 15 in Adult Congenital Heart Disease.

Baggen VJ, van den Bosch AE, Eindhoven JA, Schut AW, Cuypers JA, Witsenburg M, de Waart M, van Schaik RH, Zijlstra F, Boersma E, Roos-Hesselink JW.

Circulation. 2017 Jan 17;135(3):264-279. doi: 10.1161/CIRCULATIONAHA.116.023255. Epub 2016 Nov 3.

33.

A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients.

Oosten AW, Abrantes JA, Jönsson S, Matic M, van Schaik RHN, de Bruijn P, van der Rijt CCD, Mathijssen RHJ.

Clin Pharmacokinet. 2017 Jul;56(7):733-746. doi: 10.1007/s40262-016-0471-7.

34.

Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention.

Mitropoulou C, Fragoulakis V, Rakicevic LB, Novkovic MM, Vozikis A, Matic DM, Antonijevic NM, Radojkovic DP, van Schaik RH, Patrinos GP.

Pharmacogenomics. 2016 Oct 21. [Epub ahead of print]

PMID:
27767438
35.

Implication of UGT2B15 Genotype Polymorphism on Postoperative Anxiety Levels in Patients Receiving Lorazepam Premedication.

Mijderwijk H, Klimek M, van Beek S, van Schaik RH, Duivenvoorden HJ, Stolker RJ.

Anesth Analg. 2016 Nov;123(5):1109-1115.

PMID:
27622723
36.

Genetic variants associated with thermal pain sensitivity in a paediatric population.

Matic M, van den Bosch GE, de Wildt SN, Tibboel D, van Schaik RH.

Pain. 2016 Nov;157(11):2476-2482.

PMID:
27541715
37.

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.

Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RHN, Slawin KM, Marks LS, Catalona WJ.

BJU Int. 2017 Jul;120(1):61-68. doi: 10.1111/bju.13676. Epub 2016 Nov 22.

38.

The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.

Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik RH, Danesi R.

Eur Urol. 2017 Apr;71(4):680-687. doi: 10.1016/j.eururo.2016.08.012. Epub 2016 Oct 10.

PMID:
27733296
39.

Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck?

Danesi R, Del Re M, Ciccolini J, Schellens JHM, Schwab M, van Schaik RHN, van Kuilenburg ABP.

Ann Oncol. 2017 Jan 1;28(1):183. doi: 10.1093/annonc/mdw448. No abstract available.

PMID:
27687313
40.

Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy.

Vozikis A, Cooper DN, Mitropoulou C, Kambouris ME, Brand A, Dolzan V, Fortina P, Innocenti F, Lee MT, Leyens L, Macek M Jr, Al-Mulla F, Prainsack B, Squassina A, Taruscio D, van Schaik RH, Vayena E, Williams MS, Patrinos GP.

Public Health Genomics. 2016;19(6):352-363. doi: 10.1159/000449152. Epub 2016 Sep 28. Review.

41.

A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.

Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši Ľ, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Setric J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, Patrinos GP.

PLoS One. 2016 Sep 16;11(9):e0162866. doi: 10.1371/journal.pone.0162866. eCollection 2016. Erratum in: PLoS One. 2017 Feb 16;12 (2):e0172595.

42.

Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis.

Thijs JL, Van Der Geest BAM, Van Der Schaft J, Van Den Broek MP, Van Seggelen WO, Bruijnzeel-Koomen CAF, Hijnen DJ, Van Schaik RH, De Bruin-Weller MS.

J Dermatolog Treat. 2017 May;28(3):242-245. doi: 10.1080/09546634.2016.1227420. Epub 2016 Sep 13.

PMID:
27549213
43.

Minimum information required for a DMET experiment reporting.

Kumuthini J, Mbiyavanga M, Chimusa ER, Pathak J, Somervuo P, Van Schaik RH, Dolzan V, Mizzi C, Kalideen K, Ramesar RS, Macek M, Patrinos GP, Squassina A.

Pharmacogenomics. 2016 Sep;17(14):1533-45. doi: 10.2217/pgs-2016-0015. Epub 2016 Aug 22.

PMID:
27548815
44.

Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.

Bins S, Lenting A, El Bouazzaoui S, van Doorn L, Oomen-de Hoop E, Eskens FA, van Schaik RH, Mathijssen RH.

Pharmacogenomics. 2016 Sep;17(14):1483-90. doi: 10.2217/pgs-2016-0063. Epub 2016 Aug 17.

PMID:
27533851
45.

Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin.

Zhou K, Yee SW, Seiser EL, van Leeuwen N, Tavendale R, Bennett AJ, Groves CJ, Coleman RL, van der Heijden AA, Beulens JW, de Keyser CE, Zaharenko L, Rotroff DM, Out M, Jablonski KA, Chen L, Javorský M, Židzik J, Levin AM, Williams LK, Dujic T, Semiz S, Kubo M, Chien HC, Maeda S, Witte JS, Wu L, Tkáč I, Kooy A, van Schaik RHN, Stehouwer CDA, Logie L; MetGen Investigators; DPP Investigators; ACCORD Investigators, Sutherland C, Klovins J, Pirags V, Hofman A, Stricker BH, Motsinger-Reif AA, Wagner MJ, Innocenti F, 't Hart LM, Holman RR, McCarthy MI, Hedderson MM, Palmer CNA, Florez JC, Giacomini KM, Pearson ER.

Nat Genet. 2016 Sep;48(9):1055-1059. doi: 10.1038/ng.3632. Epub 2016 Aug 8.

46.

Opioid treatment failure in cancer patients: the role of clinical and genetic factors.

Oosten AW, Matic M, van Schaik RH, Look MP, Jongen JL, Mathijssen RH, van der Rijt CC.

Pharmacogenomics. 2016 Aug;17(13):1391-403. doi: 10.2217/pgs-2016-0082. Epub 2016 Jul 29. Erratum in: Pharmacogenomics. 2017 May;18(7):743-748.

PMID:
27472837
47.

CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.

Zhu L, Brüggemann RJ, Uy J, Colbers A, Hruska MW, Chung E, Sims K, Vakkalagadda B, Xu X, van Schaik RH, Burger DM, Bertz RJ.

J Clin Pharmacol. 2017 Feb;57(2):235-246. doi: 10.1002/jcph.798. Epub 2016 Aug 23.

PMID:
27432796
48.

Pre-examination factors affecting molecular diagnostic test results and interpretation: A case-based approach.

Payne DA, Baluchova K, Peoc'h KH, van Schaik RHN, Chan KCA, Maekawa M, Mamotte C, Russomando G, Rousseau F, Ahmad-Nejad P; IFCC Committee for Molecular Diagnostics (C-MD).

Clin Chim Acta. 2017 Apr;467:59-69. doi: 10.1016/j.cca.2016.06.018. Epub 2016 Jun 16.

PMID:
27321365
49.

The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.

Prytuła AA, Cransberg K, Bouts AH, van Schaik RH, de Jong H, de Wildt SN, Mathôt RA.

Clin Pharmacokinet. 2016 Sep;55(9):1129-43. doi: 10.1007/s40262-016-0390-7.

PMID:
27138785
50.

Population Pharmacokinetics of Prednisolone in Relation to Clinical Outcome in Children With Nephrotic Syndrome.

Teeninga N, Guan Z, Stevens J, Kist-van Holthe JE, Ackermans MT, van der Heijden AJ, van Schaik RH, van Gelder T, Nauta J.

Ther Drug Monit. 2016 Aug;38(4):534-45. doi: 10.1097/FTD.0000000000000308.

PMID:
27120177

Supplemental Content

Loading ...
Support Center